In vivo c-Met pathway inhibition depletes human glioma xenografts of tumor-propagating stem-like cells

Translational Oncology

Volumn 6, Issue 2, 2013, Pages 104-111

  Rath, Prakash ^a   Lal, Bachchu ^a   Ajala, Olutobi ^a   Li, Yunqing ^a   Xia, Shuli ^a   Kim, Jin ^b   Laterra, John ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Galaxy Biotech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CRIZOTINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L2G7; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR XENOGRAFT;

EID: 84875800035     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13127     Document Type: Article

References (33)

1. Vescovi AL, Galli R, and Reynolds BA (2006). Brain tumour stem cells. Nat Rev Cancer 6(6), 425-436.
2. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, and Rich JN (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120), 756-760.
3. Haar CP, Hebbar P, Wallace GC IV, Das A, Vandergrift WA III, Smith JA, Giglio P, Patel SJ, Ray SK, Banik NL, et al. (2012). Drug resistance in glioblastoma: a mini review. Neurochem Res 37(6), 1192-1200.
4. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, and Rich JN (2009). The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8(20), 3274-3284.
5. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nister M, et al. (2010). A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2α. Brain 133(pt 4), 983-995.
6. Wang SD, Rath P, Lal B, Richard JP, Li Y, Goodwin CR, Laterra J, and Xia S (2012). EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene 31, 5132-5143.
7. Trusolino L, Bertotti A, and Comoglio PM (2010). MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11(12), 834-848.
8. Abounader R and Laterra J (2005). Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7(4), 436-451.
9. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, and Vande Woude GF (1997). Met and hepatocyte growth factor/ scatter factor expression in human gliomas. Cancer Res 57(23), 5391-5398.
10. Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, and Abounader R (2005). The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 65(20), 9355-9362.
11. Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, and Laterra J (2006). Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 12(4), 1292-1298.
12. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, and Lamszus K (2006). A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12(20 (pt 1), 6144-6152.
13. De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D'Ambrosio A, Porrati P, et al. (2012). The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 72(17), 4537-4550.
14. Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, Kang YJ, Lathia JD, Cheong KH, Song PH, et al. (2012). MET signaling regulates glioblastoma stem cells. Cancer Res 72(15), 3828-3838.
15. Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cazares H, Eberhart CG, et al. (2011). c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci USA 108(24), 9951-9956.
16. Pandita A, Aldape KD, Zadeh G, Guha A, and James CD (2004). Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39(1), 29-36.
17. Chaichana K, Zamora-Berridi G, Camara-Quintana J, and Quinones-Hinojosa A (2006). Neurosphere assays: growth factors and hormone differences in tumor and nontumor studies. Stem Cells 24(12), 2851-2857.
18. Ferrari D, Binda E, De Filippis L, and Vescovi AL (2010). Isolation of neural stem cells from neural tissues using the neurosphere technique. Curr Protoc Stem Cell Biol Chapter 2, Unit2D 6.
19. Ying M, Sang Y, Li Y, Guerrero-Cazares H, Quinones-Hinojosa A, Vescovi AL, Eberhart CG, Xia S, and Laterra J (2011). Kruppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells. Stem Cells 29(1), 20-31.
20. Carlson BL, Pokorny JL, Schroeder MA, and Sarkaria JN (2011). Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol Chapter 14, Unit 14 16.
21. Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, and Laterra J (2009). EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther 8(7), 1751-1760.
22. Lal B, Xia S, Abounader R, and Laterra J (2005). Targeting the c-Met pathway potentiates glioblastoma responses to γ-radiation. Clin Cancer Res 11(12), 4479-4486.
23. Bleau AM, Howard BM, Taylor LA, Gursel D, Greenfield JP, Lim Tung HY, Holland EC, and Boockvar JA (2008). New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans. Neurosurg Focus 24(3-4), E28.
24. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, and Vescovi A (2004). Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64(19), 7011-7021.
25. Sun P, Xia S, Lal B, Eberhart CG, Quinones-Hinojosa A, Maciaczyk J, Matsui W, Dimeco F, Piccirillo SM, Vescovi AL, et al. (2009). DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells 27(7), 1473-1486.
26. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, et al. (2006). Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/ c-Met-dependent human tumors. Cancer Res 66(3), 1721-1729.
27. Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, et al. (2012). Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci USA 109(2), 570-575.
28. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, and Johns TG (2009). The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11(5), 448-458, 2 p following 458.
29. Li Y and Laterra J (2012). Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res 72(3), 576-580.
30. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D, and Holland EC (2010). Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6(2), 141-152.
31. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, and Miyazono K (2009). Autocrine TGF-β signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5(5), 504-514.
32. Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A, and Tahara H (2011). Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA 108(30), 12425-12430.
33. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, et al. (2010). Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6(5), 421-432.